miRNAs in platelet-poor blood plasma and purified RNA are highly stable: a confirmatory study

Dillon C. Muth†, Bonita H. Powell†, Zezhou Zhao¹ and Kenneth W. Witwer¹,²*

Abstract

Objective: We wished to re-assess the relative stability of microRNAs (miRNAs) as compared with other RNA molecules, which has been confirmed in many contexts. When bound to Argonaute proteins, miRNAs are protected from degradation, even when released into the extracellular space in ribonucleoprotein complexes, and with or without the protection of membranes in extracellular vesicles. Purified miRNAs also appear to present less of a target for degradation than other RNAs. Although miRNAs are by no means immune to degradation, biological samples subjected to prolonged incubation at room temperature, multiple freeze/thaws, or collection in the presence of inhibitors like heparin, can typically be remediated or used directly for miRNA measurements.

Results: Here, we provide additional confirmation of early, well validated findings on miRNA stability and detectability. Our data also suggest that inadequate depletion of platelets from plasma may explain the occasional report that freeze–thaw cycles can adversely affect plasma miRNA levels. Overall, the repeated observation of miRNA stability is again confirmed.

Keywords: microRNA, Stability, qPCR, Freeze/thaw, Blood processing, Plasma, RNA isolation

Introduction

microRNAs (miRNAs) are short (22 nucleotides on average) RNA molecules that contribute to post-transcriptional gene fine-tuning [1, 2] and have aroused attention as potential biomarkers of disease [3–6] in part because of their stability. In cells, mature miRNAs are relatively long-lived [7–10], with estimated half-lives ranging from around 8 h [11] to an astounding 3 weeks in certain quiescent cells [12]. In contrast, messenger RNAs have short half-lives, often of only several minutes long [13]. Outside the cell [14], miRNAs are also highly stable. They resist degradation in plasma kept at room temperature for up to 24 h or frozen and thawed up to eight times [15]. These findings have been confirmed repeatedly [16–21] and are due to the “life-long,” tight association of mature miRNAs with Argonaute (AGO) proteins [9, 22–25]. Without this association, miRNAs are rapidly degraded in the RNase-rich biological compartments with a half-life of seconds [15].

Despite a strong apparent consensus on miRNA stability, there have also been several seemingly contradictory observations. Certain tissue-specific miRNAs in circulation, like miR-1 (muscle) or miR-122 (hepatocytes), have been reported to be more sensitive to freeze/thaw than others [26]. Decreased detection of several plasma miRNAs after freeze/thaw cycles [27] or incubation of plasma at room temperature [28] was recently reported. To help resolve these apparent differences, we re-examined stability of several commonly investigated miRNAs in platelet-rich and platelet-poor plasma after incubation of plasma at 22 °C and after various freeze–thaw cycles. Since platelets—which are exquisitely temperature-sensitive and may be more susceptible to freeze–thaw damage than smaller carriers of miRNA—are not removed from
plasma unless several centrifugations or other interventions are performed [29], we hypothesized that the profound influence of platelets may explain apparently contradictory findings in the literature.

Main text

Methods

Blood processing and plasma treatments

Fresh blood from human donors was obtained under a university-approved protocol (JHU IRB #CR00011400). Blood was collected into 60 mL syringes pre-loaded with 6 mL anticoagulant Acid Citrate Dextrose (ACD) (Sigma Aldrich, St. Louis, MO. Cat #: C3821. Lot #: SLBQ6570 V). Whole blood was centrifuged within 15 min of draw at 1300 × g for 15 min to pellet blood cells. Supernatant (platelet-rich plasma or PRP) was aliquoted for later use or centrifuged twice at 2500 × g for 15 min. Supernatant from the final spin was defined as PPP. Three separate aliquots of both PRP and PPP were used for RNA extraction for each of the following conditions: fresh (immediate RNA isolation); one, two, three, four, five, and six freeze–thaw cycles (−80 to 22 °C), conducted regularly over 4 days and with rapid thaw; and 24-h incubation at 22 °C.

RNA extraction

RNA was extracted from 200 µL of plasma using the Exiqon Biofluids kit as described previously [30], including glycogen as carrier. RNA was stored at −80 °C until use unless otherwise specified.

RNA stability experiment

Aliquots of purified plasma RNA were frozen at −80 °C, then thawed and incubated at room temperature for 7, 3, 1, and 0 days in a “countdown” design as previously described for shorter time periods [31]. For the RNase A control, RNA was completely degraded by addition of equal volume RNase A (ThermoFisher, #EN0531, stock solution 10 mg/mL) prior to reverse transcription.

qPCR assays

miRNA stem–loop reverse transcription quantitative PCR [32] was done as previously described [30] but using 384-well plates. Synthetic cel-miR-39-3p (Qiagen, #219610) was included in the reverse transcription master mix as a spike-in. Input into the reverse transcription reaction was normalized by volume (3 µL for plasma RNA). Assays were obtained from Applied Biosystems/Thermo Fisher, Cat. # 4427975: hsa-miR-16-5p (part number 000391), hsa-miR-21-5p (000397), and cel-miR-39-3p (000200). The quantitative step was done by following the manufacturer’s directions for cycling on a QuantStudio 12 K Flex Real-Time PCR System (Thermo Fisher).

Data and material availability

All data collected during this study are available upon request. Materials are specified in the relevant methods sections so that researchers wishing to repeat the experiments can use the same reagents. Purified RNA has been used for this study or related studies and is unlikely to be available to other researchers in sufficient quantities.

Results

Stability of miRNA in fresh versus frozen platelet-rich and -poor blood plasma

Whole blood samples were processed to PRP immediately after draw. PPP was produced from a portion of the PPP. To assess effect of freeze–thaw cycle, PRP and PPP were frozen at −80 °C and thawed for a total of one through six cycles before RNA isolation. Triplicate aliquots were processed for each condition, and miRs-16-5p and -21-5p were measured by RT-qPCR. As shown in Fig. 1, fresh PRP contained several fold more of both miRNAs than fresh PPP, with the difference attributable to the presence of platelets in the former. Compared with freshly processed plasma (“fresh”), a single freeze–thaw cycle increased cycle numbers for detection of both miRNAs. Additional cycles of freeze–thaw had no consistent additional effect (Fig. 1, FT 1–6). In contrast, miRNAs in PPP were insensitive to freeze–thaw. Although some technical variability was observed (see especially the outlier points FT3 for donor 1 plasma and FT1 for donor 2, Fig. 1), the average Cq of miRNAs extracted from frozen/thawed PPP was indistinguishable from that of fresh plasma. There was no consistent trend towards higher Cq with higher numbers of freeze–thaw cycles.

Stability of miRNA in plasma to incubation at room temperature

In parallel with the freeze–thaw experiments, aliquots of PRP and PPP were incubated at room temperature (approximately 22 °C) for 24 h before RNA isolation. PRP displayed a slight increase in Cq values for both miRNAs after this incubation, although not as pronounced as for the initial freeze–thaw cycle. Similar to the freeze–thaw results, miRNAs in PPP appeared to be insensitive to room temperature incubation (Fig. 1, RT 24).

Stability of miRNA in purified RNA

We have previously reported the stability of purified miRNAs in aqueous solution when incubated at room temperature for time periods ranging from 0 to 24 h [31]. We confirmed and extended this observation for miR-16-5p in total plasma RNA purified using the
Exiqon Biofluids kit. RNA was incubated at 22 °C for 0, 1, 3, and 7 days prior to qPCR. A slight increase in average Cq was observed after 7 days at room temperature (Fig. 2). However, the range of values at day 7 overlapped with those from other days and the difference was not significant. Addition of RNase A resulted in complete loss of signal.

Conclusions

This study re-examined stability of miRNAs in blood plasma, probing abundance of miRNAs in PRP and PPP subjected to eight conditions including freeze–thaw (one to six cycles) and incubation at room temperature for 24 h. Each condition was represented in three processing replicates (a total of 96 plasma and RNA samples) and three qPCR measurements of RNA from each processing replicate. Using the majority of miRNAs in platelet-rich plasma [29, 31], and those results again reinforce that platelets contain the majority of miRNAs in platelet-rich plasma [29, 31], and that platelets are more susceptible to a single freeze–thaw cycle or incubation at room temperature than smaller mRNA carriers such as exRNPs and EVs that remain after platelet removal. Once damage of platelets occurs in platelet-rich plasma, additional freeze–thaw cycles do not appear to exacerbate miRNA loss; instead, these miRNAs are highly stable [15–21]. While it is possible that different miRNAs would yield different results, this is most likely to occur in PRP and for miRNAs with possibly but to a lesser extent, by incubation at room temperature for 24 h. However, freeze–thaw cycles after the initial cycle had no consistent effect on miRNA abundance. Instead, these miRNAs are highly stable [15–21].
different abundance ratios in platelets versus true exRNA fractions. Studies that aim to examine truly extracellular plasma RNA must include careful separation of platelets and their RNA from other RNA sources.

Another potentially important conclusion is that small fold changes in extracellular miRNAs require multiple time points and replicates on which to base any firm conclusions. In this experiment, operators with multiple years of experience with RNA SOPs nevertheless observed anomalous results for several time points or conditions. These results could have led to incorrect conclusions if examined in isolation. For example, the “freeze–thaw 3” condition for PPP (donor 1) and the “freeze–thaw 1” condition for PPP (donor 2) appeared to show an increase in miRNA detection that was not seen for the spiked-in control. The differences we observed were clearly artifactual and introduced at some post-processing or RNA purification step, as a synthetic sequence spiked in just before qPCR was consistently and relatively invariantly detected for all conditions. Without the context of the other conditions/time points, these results might not have been identified as outliers and could have been incorrectly interpreted.

The remarkable stability of miRNAs, both in biological matrices and after RNA purification, has made miRNAs into attractive perceived biomarkers despite their comparative dearth of information content. Protected by a tight association with AGO proteins, mature miRNAs can be detected in biological matrices many years after tissue fixation or freezing, or after weeks or months at above-freezing temperatures, while miRNAs in purified RNA seem to present a smaller “target” for degradation and decay than other RNA species. To be sure, the best practice is always to compare directly only those samples that have been processed and treated in the same way. However, clinical samples and isolated RNA samples alike that have been stored for extended periods, left at room temperatures for hours to days, or subjected to multiple freeze–thaw cycles may still harbor miRNAs with an important tale to tell.

Limitations
These results were limited to several miRNAs that are commonly studied in circulating biomarker investigations. Other miRNAs, as well as non-miRNA RNA species, may be more or less associated with platelet artifacts.

Abbreviations
RNA: Ribonucleic acid; miRNA: microRNA; AGO: Argonaute; EV: Extracellular vesicle; qPCR: Quantitative polymerase chain reaction; RNAse: Ribonuclease; ACD: Acid citrate dextrose; PRP: Platelet-rich plasma; PPP: Platelet-poor plasma; Cq: Cycle of quantitation; RT: Room temperature.

Authors’ contributions
DCM, BHP, and ZZ collected samples and performed experiments and analyses; KWW planned and directed the studies, conducted analyses, and wrote the manuscript; all authors contributed to editing and revision of the manuscript. All authors read and approved the final manuscript.

Author details
1 Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, 733 N. Broadway, Miller Research Building Rm 829, Baltimore, MD 21205, USA. 2 Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Acknowledgements
The authors gratefully acknowledge Mr. J. Woodland Pomeroy for assistance with donor scheduling and the JHU DNA Analysis Facility for access to the QuantStudio qPCR system.

Competing interests
The authors have no competing interests to declare. The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of the data; in the writing of the report; or in the decision to submit the report for publication.

Availability of data and materials
All data are shown in the manuscript. Any materials (RNA) remaining from the study may be available upon request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Fresh blood from human donors was obtained under a university-approved protocol (JHU IRB CR00011400). All donors consented to participate under the terms of the protocol. Consent to participate was verbal, as authorized by the institutional review board for the relatively low-risk, non-invasive phlebotomy procedure, and since no identifying or medical information was collected.

Funding
This work was supported in part by the US National Institutes of Health through R01 DA040385, a Johns Hopkins University Catalyst Award, and funds from the Department of Molecular and Comparative Pathobiology (all to KWW); by the Johns Hopkins University Center for AIDS Research, an NIH funded program (P30AI094189; summer research fellowship to ZZ); and by NIH T32 OD011089, through which DCM received support.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 29 March 2018 Accepted: 30 April 2018 Published online: 04 May 2018

References
1. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215–33.
2. Seitz H. siRNAs: the hidden face of the small RNA world. Curr Biol. 2010;20(3):R108–10.
3. Fabbri M. miRNAs as molecular biomarkers of cancer. Expert Rev Mol Diagn. 2010;10(4):435–44.
4. Moldovan L, Batte KE, Trgovcich J, Wisler J, Marsh CB, Piper M. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med. 2014;18(3):371–90.
5. Weiland M, Gao XH, Zhou L, Mi QS. Small RNAs have a large impact: circulating microRNAs as biomarkers for human diseases. RNA Biol. 2012;9(6):850–9.
6. Wittwer KW, Halushka MK. Toward the promise of microRNAs—enhancing reproducibility and rigor in microRNA research. RNA Biol. 2016;13(1):1103–16.

7. Li Y, Li Z, Zhou S, Wen J, Geng B, Yang J, et al. Genome-wide analysis of human microRNA stability. Biomed Res Int. 2013;2013:369975.

8. Rüegger S, Großhans H. MicroRNA turnover: when, how, and why. Trends Biochem Sci. 2012;37(10):436–46.

9. Marzi MJ, Ghini F, Cerruti B, de Pretis S, Bonetti P, Giamelli C, et al. Degradation dynamics of microRNAs revealed by a novel pulse-chase approach. Genome Res. 2016;26(4):534–65.

10. Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, et al. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. Nucleic Acids Res. 2011;39(13):5692–703.

11. Bail S, Sveder M, Liu H, Jiao X, Goff LA, Hart RP, et al. Differential regulation of microRNA stability. RNA. 2010;16(5):1032–9.

12. Olczynszak SH, La Rocca G, Gruber JJ, Thompson CB. Long-lived microRNA-Argonauta complexes in quiescent cells can be activated to regulate mitogenic responses. Proc Natl Acad Sci USA. 2013;110(1):157–62.

13. Baudrimont M, Voegeli S, Villoa EC, Sirit F, Lenon M, Wada T, et al. Multiplexed gene control reveals rapid mRNA turnover. Sci Adv. 2017;3(7):e1700066.

14. Nelson PT, Baldwin DA, Scearce LM, Oberholtzer JC, Tobias JW, Mourelatos Z. Microarray-based, high-throughput gene expression profiling of microRNAs. Nat Methods. 2004;1(2):155–61.

15. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105(30):10513–8.

16. Exiqon.com. Biofluids guidelines: analyzing microRNAs in liquid biopsies. Report no. 4.0. http://www.exiqon.com/fs/Documents/Scientific/microRNA-serum-plasma-guidelines.pdf. Accessed 5 Nov 2017.

17. Glid S, Meiri E, Yogev Y, Benjamim S, Lebanoyn D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS ONE. 2008;3(9):e3148. https://doi.org/10.1371/journal.pone.0003148.

18. Shaffer J, Schlumberger M, Lader E. miRNA profiling from blood: challenges and recommendations. 2012. http://sabiosciences.com/manuals/Whitepaper_Serumplasma.pdf. Accessed 5 Nov 2017.

19. Lv L-L, Cao Y, Liu D, Xu M, Liu H, Tang R-N, et al. Isolation and quantification of microRNAs from urinary exosomes/microvesicles for biomarker discovery. Int J Biol Sci. 2013;9(10):1021–31.

20. Miranda KC, Bond DT, McKee M, Skog J, Paunescu TG, Da Silva N, et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 2010;78(2):191–9.

21. Miranda KC, Bond DT, Levin JZ, Adiconis X, Sivachenko A, Russ C, et al. Massively parallel sequencing of human urinary exosome/microvesicle RNA reveals a predominance of non-coding RNA. PLoS ONE. 2014;9(5):e96094.

22. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16):7223–33.

23. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012;37(11):460–5.

24. Arroyo JD, Chevillet JR, Kroh EM, Ruik IF, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA. 2011;108(12):5003–8.

25. McKenzie AJ, Hoshino D, Hong NH, Cha DJ, Franklin JL, Coffey RJ, et al. KRAS-MEK signaling controls ago2 sorting into exosomes. Cell Rep. 2016;15(5):978–87.

26. Koberle V, Piel T, Schmihals C, Augusto Alonso E, Haupenthal J, Bö nig H, et al. Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers. PLoS ONE. 2013;8(9):e75184.

27. Glinge C, Clauss S, Boddmann K, Jabbari R, Jabbari J, Risaard B, et al. Stability of circulating blood-based microRNAs—pre-analytical methodological considerations. PLoS ONE. 2017;12(2):e0167969.

28. Wang L, Sadi M, Giraud D, Zempleni J. RNase H2-dependent polymerase chain reaction and elimination of confounders in sample collection, storage, and analysis strengthen evidence that microRNAs in bovine milk are bioavailable in humans. J Nutr. 2018;148(1):153–9.

29. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, et al. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PLoS ONE. 2013;8(6):e64795.

30. McAlexander MA, Phillips MJ, Wittwer KW. Comparison of methods for miRNA extraction from plasma and quantitative recovery of RNA from cerebrospinal fluid. Front Genet. 2013;4:83.

31. Witwer K, Auerbach A, Vyas G, Li A, Halushka M. Uptake of dietary milk miRNAs by adult humans: a validation study. F1000Research. 2016. http://www.scopus.com/inward/record.url?eid=2-s2.0-8497847301&partnerID=MN8TOAR5.

32. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005;33(20):e179.

33. Mitchell AJ, Gray WD, Hayek SS, Ko Y-A, Thomas S, Rooney K, et al. Platelets confound the measurement of extracellular miRNA in archived plasma. Sci Rep. 2016;6(1):32651.